Search results for: 'Preferred Destination for Clinical Trials 2020'

12 May 2025  |  Global  |  Market Research

Clinical Decision Support System Market, Global, 2024–2030

AI Integration is Driving Transformational Growth by Enabling Improvements in Clinical Outcomes

Infographics

×

The increasing focus on effective population health management is prompting healthcare organizations to adopt next-generation clinical decision support tools that drive market growth. Healthcare systems continue to face significant clinical quality and efficiency challenges, leading to a heightened focus on implementing clinical decision support sy...

The COVID-19 pandemic impact on the biopharmaceutical industry has increased patient-centricity and the adoption of eClinical services digital platforms to manage clinical development programs. Capital investments and co-development recorded an uptick over the last 2 years, focusing on advancing clinical assets and expanding the number of Phase 2 a...

06 Jul 2021  |  North America  |  Market Research

Global Decentralized Clinical Trial (DCT) Growth Opportunities

Strategic Partnering and M&A Activity in At-home Monitoring Solutions Gain Momentum

Infographics

×

Frost & Sullivan presents post–COVID-19 growth opportunities and strategic imperatives for the global decentralized clinical trials (DCT) market, covering the markets maturity, key participants, adoption drivers and restraints, and recent mergers and acquisitions. The report identifies initiatives by major global contract research organizations (CR...

Worldwide cancer incidence is expected to exceed 35 million new cases by 2050, a 77% rise from the 20 million cases in 2022. Alcohol intake, tobacco usage, obesity, and air pollution are the main causes of this increase. Cancer studies today emphasize cell and gene therapy, antibody-drug conjugates (ADCs), checkpoint inhibitors, and multi-specific...

COVID-19 has accelerated the need for a faster, more accessible clinical trial process. During the height of the pandemic, in-person follow-ups for ongoing trials were replaced with hand-held devices that essentially built an ecosystem for home health care support services that can be easily leveraged to avoid or reduce participant dropout rates. ...

21 Aug 2020  |  Global  |  Market Research

Hybridization of Clinical Trial Designs Reviving Global CRO Market Post-pandemic, 2019–2024

Patient-centric and Safety-focused Logistical Solutions will Create New Growth Opportunities

Infographics

×

In this research deliverable, Frost & Sullivan’s analyst team offers a bold perspective on the post-pandemic growth opportunities for the global CRO market. With the increased threat of COVID-19 and world-wide lockdowns in effect, the contract research organization (CROs) market is seeing interruptions in ongoing clinical trials and delays of new t...

08 Nov 2024  |  Global  |  Market Research

Analysis of the Clinical Next-generation Sequencing Sector, Global, 2024-2030

Continued Investment in AI is Driving Transformational Growth by Accelerating Information Solutions Development

Infographics

×

This Frost & Sullivan analysis examines the clinical next-generation sequencing (NGS) industry, covering the different type of products, workflows, and applications for clinical purposes. The global market is projected to grow steadily from 2024 to 2030, achieving significant revenue milestones, driven largely by services and informatics segments. ...

31 Aug 2020  |    |  Technology Research

Data Science Impacting the Pharmaceutical Industry Part II: Clinical trial Applications

Enabling faster analysis using advanced tools

Infographics

×

Clinical Trials, the most crucial step in drug discovery has never been in the forefront in adopting new technologies and transforming from the conventional protocols. With the development of AI/ML in the last five years, it has opened up a new horizon for transforming clinical trials. It has been proven that use of AI/ML tools can scan through la...

More than 6,000 molecules are currently in clinical development across the pharmaceutical research and development (R&D) landscape, with more than 11,000 in the preclinical phase. The industry is witnessing the growth of small- to mid-segment pharma/biotech players making significant contributions to drug discovery and development pipelines. Across...